No Data
No Data
US Investors Beware: Tax Complications for Can-Fite BioPharma Shareholders
Can-Fite BioPharma Reports Reduced Losses in 2023
Can Fite Biofarma: Q4 Earnings Insights
Can Fite Biofarma (AMEX:CANF) reported its Q4 earnings results on Thursday, March 28, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsCan Fite Biofarma beat estimate
Can Fite Biofarma FY GAAP EPS $(0.01), Same YoY, Sales $743.00K Down From $810.00K YoY
Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $743.00 thousand in sales this quarter. This is a
Can-Fite Biopharma GAAP EPS of -$0.01, Revenue of $0.74M
Namodenoson Treatment for Pancreatic and Liver Cancer: Data Will Be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, today announced its VP of Business Development, Dr. Sari Fishman, will present data from the pancreatic and liver cancer programs during numerous partnering meetings at the BIO-Europe Spring 2024 in Barcelona, Spain, on Mar 18-27, 2024
No Data